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Abstract
Background: There is a need for more Comparative Effectiveness Research (CER) on Chinese medicine (CM) to
inform clinical and policy decision-making. This document aims to provide consensus advice for the design of CER
trials on CM for researchers. It broadly aims to ensure more adequate design and optimal use of resources in
generating evidence for CM to inform stakeholder decision-making.
Methods: The Effectiveness Guidance Document (EGD) development was based on multiple consensus procedures
(survey, written Delphi rounds, interactive consensus workshop, international expert review). To balance aspects of
internal and external validity, multiple stakeholders, including patients, clinicians, researchers and payers were
involved in creating this document.
Results: Recommendations were developed for “using available data” and “future clinical studies”. The
recommendations for future trials focus on randomized trials and cover the following areas: designing CER studies,
treatments, expertise and setting, outcomes, study design and statistical analyses, economic evaluation, and
publication.
Conclusion: The present EGD provides the first systematic methodological guidance for future CER trials on CM
and can be applied to single or multi-component treatments. While CONSORT statements provide guidelines for
reporting studies, EGDs provide recommendations for the design of future studies and can contribute to a more
strategic use of limited research resources, as well as greater consistency in trial design.
Keywords: Comparative effectiveness research, Effectiveness guidance document, Chinese medicine research
Background
Chinese medicine (CM) includes a broad range of medical
practices that have many of their roots in China and share
common theoretical concepts. According to the descrip-
tion by the National Center for Complementary and Al-
ternative Medicine (NCCAM) CM ‘encompasses many
different practices, including acupuncture, moxibustion
(burning an herb above the skin to apply heat to acupunc-
ture points), Chinese herbal medicine, tuina (Chinese
therapeutic massage), dietary therapy, and tai chi and
qigong (practices that combine specific movements or
postures, coordinated breathing, and mental focus) [1].
In general, CM follows a theoretical framework, and the
etiology and pathogenesis of CM uses its own termin-
ology. The processes of diagnoses and interventions of this
medical system are different from those in conventional
medicine, and both are guided by traditional principles of
CM. CM is often used as a multi-component treatment in
which cultural, philosophical, historical, temporal, and
geographic aspects as well practitioner training, all influ-
ence its heterogeneity.
From the practitioner’s perspective, CM diagnoses (for
example, bian zheng), often also called CM patterns or
CM syndromes differentiation, inform CM interventions.
To date, treatment individualization according to the
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http://www.trialsjournal.com/content/15/1/169CM diagnoses seems to have very little clinically relevant
impact on the outcome of acupuncture treatment in
clinical studies [2-4], whereas it might be more relevant
for clinical trials of CM pharmacotherapy [5,6], although
evidence is still scarce. In practice, CM treatment is often
individualized, and because CM diagnoses may change
over time, interventions can also change during the course
of treatment. Currently in China, standardization of CM
diagnoses and treatment for practice and research is
emphasized, whereas in the West, a trend toward more
individualization in research protocols and in practice is
observed.
Aim of the document
This document provides consensus advice for the design
of comparative effectiveness research (CER) trials in CM
for researchers. CER is the generation and synthesis of
evidence that compares the benefits and harms of alter-
native treatment options to prevent, diagnose, treat, and
monitor a clinical condition or to improve the delivery
of care. The purpose of CER is to assist consumers, cli-
nicians, purchasers, and policy makers to make informed
decisions that will improve health care at both the indi-
vidual and population levels [7].
CER broadly aims to ensure more adequate design and
optimal use of resources in generating evidence for CM
to inform stakeholder decision-making. These consensus
recommendations can be applied to single and multi-
component interventions. They are based on the assump-
tion that a reduction of internal validity can be justified
in order to increase authenticity of the intervention and
setting, thereby enhancing generalizability, relevance,
feasibility and timeliness of research results.
Methods
The development of the Effectiveness Guidance Docu-
ment (EGD) followed a structured and predefined consen-
sus process, which included a pre-workshop online survey
(April 2012), a consensus workshop (19 May 2012 in
Portland, OR, USA), and three written Delphi rounds
(August 2012, January 2013 and May 2013) utilizing writ-
ten comments to finalize the document.
Multiple stakeholders were involved in the consensus
process for this EGD to balance aspects of internal and
external validity in the recommendations. Participants of
the workshop had the following backgrounds: one CM
patient, one health insurance representative, nine experts
in CM with experience in both CM practice and CM re-
search (two from China, two with a Chinese background
living in the USA, four from the USA, and one from
UK), and 6 methodologists (with backgrounds in clinical
research, statistics or epidemiology, 5 of them with experi-
ence in CM research). The consensus meeting utilized
presentations, large group discussions and an adapted
world café methodology. The world café method, as devel-
oped by Brown and Isaac, is a simple, effective, and flex-
ible format for facilitating large group dialogue [8]. It has
been used in the development of prior EGDs [9] to foster
collaborative dialogue, knowledge sharing, and commu-
nity participation in a setting that involves multiple stake-
holder groups.
Expert involvement was further broadened by the inclu-
sion of nine international CM research experts who did
not participate in the workshop, but who contributed to
the survey and both Delphi rounds. The consensus
process was finalized after feedback from all workshop
participants and the external review experts.
Results
The results of the consensus process are presented in two
sections: I) Using available data, II) recommendations for
future clinical studies.
I) Using available data
1) Clinical Health Records
a) Data from clinical health records are
important and can be very useful for
generating hypotheses for future randomized
trials, identifying common diagnostic patterns
and promising interventions, assisting
recruitment for prospective studies, correlating
CM diagnoses with outcomes, and providing
information on patient characteristics and
interventions in usual care.
b) The potential for CER based on clinical health
records that document CM use (for example,
Kaiser Permanente California [10,11], Veterans’
Administration [12]) needs more exploration.
The value of such records depends on the
documentation structure and the availability of
data on useful surrogate outcomes such as
visits, days off from work, drug use, and/or
costs.
2) Data from previous trials
a) Databases provide helpful information on
existing CM trials (for example, Oregon
College of Oriental Medicine for Acupuncture
(AcuTrials®)[ 13], New England School of
Acupuncture (NESA) Database [14], Chinese
BioMedical Literature Database (CBM) [15],
China Network Knowledge Infrastructure
(CNKI) [16], and Chinese Scientific Journals
Database (VIP) [17]).
b) There is a need to develop a database of CM
trials that have included multi-component
treatments.
c) Patient level raw data from randomized trials
on CM should be shared in order to generate a
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for all new trials. Guidelines to facilitate such
sharing should be developed and implemented.
II) Recommendations for future clinical studies
The recommendations are summarized under the
following headings:
 Designing CER studies
 Treatments, expertise and setting
 Outcomes
 Study design and statistical analyses
 Economic evaluation
 Publication
Design and reporting guidelines relevant to these rec-
ommendations are summarized in Table 1. A checklist
highlighting the most important elements is presented in
Table 2.
Designing CER studies
1) Stakeholder engagement
a) Involvement of all relevant stakeholders (for
example, practitioners, clinicians, patients, payers,
researchers) is highly relevant for CER when
identifying research questions, planning, and
designing the study, and interpreting study results.
b) Stakeholder involvement should follow a
systematic approach (for more information on
suitable methods see Deverka et. al. [30]).
2) Study question and the efficacy-effectiveness
continuum
a) The study question should be clearly phrased,
and include all relevant information about study
participants, interventions, comparison groups
and outcome parameters. In particular, it should
clarify whether the CM treatment is to be assessed
as an “alternative” in direct comparison, using a
superiority or non-inferiority hypothesis, or as an
adjunct to a usual or standard care treatment.
b) During the trial planning phase, time should be
given to discuss and determine the trial’s position
along the efficacy-effectiveness continuum [31].
Use of the PRECIS tool to support this process is
recommended [32].
3) Study designs for complex multi-component CM
interventions
a) Pragmatic trials may be used to compare complex
multi-component treatment alternatives
(for example, multi-component CM treatment,
consisting of acupuncture, dietary advice and
qigong compared to multi-component conventional
treatment, consisting of prescribed recommendations
for exercise and diet for the treatment of mild
hypertension) [20].
b) Multi-arm trials may help to identify dosing effects,
synergistic effects when combining different CM
interventions, and effective components within one
treatment modality (for example, isolating
meditative and breathing components from
comprehensive qigong/tai chi protocols).
c) The complexity of therapeutic decision-making
and treatment changes within the treatment
process could be reflected by designs as demonstrated
by Ritenbaugh et. al. [33,34].
Study population
4) General eligibility criteria
a) In the context of available resources, eligibility
criteria should be as broad as possible. The
Table 1 Relevant guidelines for design and reporting
Document Design Reporting Reference
Effectiveness guidance document for acupuncture research X [9]
SPIRIT for content of clinical trial protocols X X [18]
CONSORT for parallel group randomized trials X [19]
CONSORT extension for pragmatic trials X[ 20]
CONSORT for non-pharmacological trials X [21]
CONSORT extension for cluster randomized trials X [22]
CONSORT extension for acupuncture trials X [23]
CONSORT extension for herbal interventions X [24]
CONSORT extension for non-pharmacological treatment interventions X [25]
CONSORT extension for traditional Chinese medicine X [26]
CONSORT extension for patient reported outcomes X [27]
Guidelines for randomized controlled trials investigating Chinese herbal medicine X [28]
Extending the CONSORT statement to moxibustion X [29]
CONSORT= Consolidated Standards of Reporting Trials.
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of usage and disease burden, and the study
population should reflect all well-known relevant
disease characteristics that may interact with the
treatment (for example, gender, disease stage,
comorbidities, co-medications).
b) Patients with comorbidities should not be
explicitly excluded from the study enrollment
unless the comorbidities make them
inappropriate candidates for the treatment, but
safety and regulatory aspects have to be taken
into account (for example, when using herbs).
c) Both CM naïve and non-naïve patients should
generally be considered eligible for study inclusion
to reflect real-world patient population. If special
groups are targeted, the rationale should be
provided.
5) Diagnosis
a) The study disease/condition should be defined as
clearly as possible from the Western medical
approach as well the CM approach.
b) In general, recruitment of patients should initially
follow the Western diagnostic approach.
c) CM diagnoses should subsequently be made in all
treatment groups (before randomization in
randomized studies) and documented whenever
Table 2 Checklist for the most relevant aspects of
comparative effectiveness research for Chinese medicine
clinical studies
Designing comparative effectiveness research (CER) studie
1. Stakeholder
involvement
All relevant stakeholders are involved in
identification of research topic, plan and design
of CER, interpretation of results
2. Efficacy-effectiveness
continuum
Location on the efficacy-effectiveness continuum
is determined for participant selection/eligibility
criteria, treatment protocol, practitioner expertise,
outcomes, and setting in which the study is
conducted
3. Study design Designs for multi-component interventions
should be considered
Study population
4. Eligibility criteria Should be as broad as possible in the context
of available resources - Study population
includes both CM-naïve and CM-non- naïve
patients
5. Diagnoses Recruitment of patients should follow Western
diagnoses - CM diagnoses should be done
whenever possible
6. Patient recruitment Patients are recruited from site(s) where the
treatment is usually provided
Treatment, expertise, and setting
7. Defining treatments If intervention involves multi-component treatment
the combination should be plausible and feasible
in usual care - non-CM best practice alternatives
are based on guidelines or broad expert consensus
8. Acupuncture See [9]
9. Qi gong/tai chi Style and setting should reflect typical
community-based programs
10. Herbal medicine Local and national regulations should be taken
into account
11. Treatment
documentation
Documentation reflects which treatments were
received by all groups (interventions and
co-interventions)
Outcomes
12. Measures Widely accepted or standardized outcome
measure used - secondary outcomes capture
relevant patient-centered dimensions for the
condition under study
13. Timing Assessment schedule is balanced allowing study
to acquire relevant data without substantial
disruption of treatment or setting
Study design and statistical analysis
14. Allocation Allocation is concealed - stratification for
subgroups and/or dynamic allocation for key
characteristics are used
15. Blinding Outcome data are kept inaccessible to
practitioners - blinded outcome rater is used if
possible
16. Preferences/
expectation
Preferences and expectations are measured at
baseline
17. Sample size Sample size takes patient heterogeneity into
account - required sample size is feasible - Study
has enough power for planned subgroup
analyses
Table 2 Checklist for the most relevant aspects of
comparative effectiveness research for Chinese medicine
clinical studies (Continued)
18. Subgroups Relevant subgroups are pre-planned - exploratory
subgroup analysis is mentioned in study aims
19. Statistical analysis Intention-to-treat analyses are planned - relevant
subgroup analyses are planned - data analyses
are adjusted for stratification variables, baseline
differences and relevant confounders
Economic evaluations
20. Relevance Setting reflects reality in clinical practice
21. Methodological
approach
Standard methods for economic evaluations are
used - sensitivity analysis is employed for all
relevant stakeholder perspectives - relevant
subgroups are identified
22. Observation time Long-term observation (≥12 months) are
planned if possible
Publications
23. Guidelines Relevant guidelines (CONSORT) are consulted
and followed
24. Content Statements of how and why this is CER are
included - study setting (including practitioner
selection procedure) is described in detail -
treatment group description from informed
consent is provided - comparison groups are
described in detail - data are provided on all
interventions and co-interventions received - relevant
subgroup analyses are reported
CM, Chinese medicine; CONSORT, Consolidated Standards of Reporting Trials.
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recognized categorization system for the CM
diagnoses should be used. The CM diagnoses
could be used for exploratory analyses and to
generate hypotheses for future studies (for
example, impact on the outcome, correlation with
genomics, prediction of the course of disease and
response to treatment in the different treatment
groups).
d) Designing the study around CM diagnoses in
general should be avoided (for example, including
only patients with one type of CM diagnosis),
because results are difficult to implement into a
medical system that follows a Western approach.
However, if a clear and limited number of CM
diagnoses exist, and research-based evidence is
available to suggest that the CM diagnoses are
reliable, consistent across practitioners, and have
a relevant influence on the intervention or the
outcome, this should be taken into account,
(for example, by stratified randomization according
to CM diagnoses, or different treatments for
different CM diagnoses).
e) If the CM diagnosis is relevant to the study
design (for example, preplanned confirmatory
subgroup analyses according to the CM
diagnoses), emphasis should be placed on
strengthening its reliability (for example, assessing
inter-rater agreement, providing training and/or
calibration of practitioners).
6) Patient recruitment
a) Recruitment should be carried out systematically
and from various sources (for example, in places
where the population suffering from the disease is
available and/or relevant treatments are usually
employed).
b) Patients’ treatment should be recorded at baseline
and efforts should be made to recruit both those
who express treatment preferences and those
who do not.
c) Appropriate strategies to ensure successful
recruitment should be developed and, if possible,
pretested.
d) In non-randomized studies, as far as possible,
recruitment strategies should be similar for all
treatment arms.
Treatment, expertise and setting
7) Defining treatment groups
a) The treatment alternatives (CM treatments and
non-CM treatments) should each provide value
to the patient by having the potential to be “best
practice” [7]. In the absence of a clear evidence
base “best practice” of CM can be derived by 1)
reviewing alternatives that have been effective in
addressing similar issues in the past and could be
applied to a current problem, and 2) integrating
information from a number of sources
(recommended research protocols, existing
clinical data, reference to classical usage, and
formal consensus procedures). If a direct
“head-to-head” comparison is used, all treatment
options should reflect usual care as much as
possible, and ideally the extent of standardization
should be similar in all treatment groups. If CM
treatment plus usual care is compared to usual care
alone, usual care should be similarly defined and
provided in both groups.
b) The comparison treatments and their complexity
should have widespread clinical acceptance
relative to the condition studied and stage of
disease.
c) The rationale for the CM treatment should follow
one of the following two approaches:
○ If there is positive evidence for single
treatment components from clinical studies,
these components may be combined to
evaluate the comparative effectiveness of a
complex multi-component treatment. The
combination of treatment components should
be plausible and feasible in a routine care
context and not contradicted by CM theory.
○ If convincing clinical evidence is not available
for the single treatment components, overall
effectiveness of a multi-component CM
treatment should be evaluated before component
efficacy is addressed. The rationale for the
treatment components and their combination
should be based on both thorough clinical
evidence and associated theory from the
literature.
d.)Non-CM comparator treatments should be based
on evidence, guidelines or broad expert
consensus.
8) Special aspects for acupuncture have been described
in the EGD for acupuncture research [9].
9) Special aspects of qigong/tai chi
a) A large number of Qigong/Tai Chi styles exist
and the chosen style(s) for a research trial should
represent to some extent the real world
heterogeneity of practice in the country where
the study is performed.
b) If a very specific style is used, it must be justified
(specific style or protocol found to be effective in
prior studies, or potential for widespread
adoption), and limits to generalizability should be
acknowledged.
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should be accessible and reflect typical
community-based programs; the longer-term
(post-study) sustainability of the program should
be considered (access to training, classes or
instruction).
d) qigong/tai chi should be provided by qualified
instructors, with expertise in both protocol
content and teaching. Training and teaching
qualifications of all instructors should be
reported. In studies of high-risk populations,
treatment safety should play a prominent role,
using more expert instructors and protocols
validated with respect to safety.
e) Studies should provide information that specifies
exercises (names and style), dose (number and
duration of classes, home exercise) and ancillary
training materials offered (for example, books and
audio-visual material).
10)Special aspects of herbal medicine
a) Study designs must comply with local and
national regulations regarding herbal medicines in
the country of the clinical trial. Although widely
used in everyday practice, and in spite of the fact
that research is urgently needed, research on
individualized, multi-herb formulations is very
difficult to accomplish in most Western countries
due to government regulations and Institutional
Review Board approval.
b) The treatment should be based on existing
evidence (systematic review of Chinese as well as
European and US-based databases, survey of
normal practice, practitioner case records, etc.),
should have “model validity” within CM, and
provide a rationale for “good practice” in CM.
c) It must be assured that the treatment does not
include any endangered species.
d) Herbal formulations that include different herbs
need to be adequately defined (chemically to
assure quality of herbs).
e) Additional safety aspects have to be taken into
account including the aspect that relevant
laboratory tests should be performed during the
trial to check for potential unwanted side effects
interactions with other medicines, although the
latter can impact study design, cost and
recruitment.
f) Relevant aspects for the different stakeholder
groups should be taken into account when
planning the treatment. This includes
consideration of:
○ Different preferences among different
stakeholder groups for the route of
administration (for example, decoction,
granules, or tablets). However, when making
changes to improve participant compliance,
care should be taken to maintain treatment
regimes and dosages that agree with standards
of “good practice”.
○ Costs of the treatment, for the research trial
per se and for the likelihood of trial results
informing clinical practice. Cost may be
affected by the complexity of the herbal
formula, as well as the dosage and route of
administration. These are important
considerations for payers and patients who
often pay out-of-pocket.
11)Treatment documentation
a) All treatments (study treatment, co-treatments,
over-the-counter self-medication) carried out in
all groups should be documented as well as the
context in which the usual care is provided. A
variety of documentation methods and sources
may contribute details (including medical records,
case report forms, patient diaries).
Outcomes
12)Measures
a) The main outcome measures should be
patient-centered and, if appropriate, include
relevant biological measures for the respective
disease/condition. Whenever possible,
diagnosis-specific validated standards for outcome
measures published by professional associations
(for example, the International Headache Society
on headache measures) [35]o rb r o a dp u b l i s h e d
expert consensus (for example, on back pain
measures) [36] should be followed to permit better
comparison of study results.
b) If no standard measures for targeted outcomes
exist, or those that are available are not suitable
for CER on CM, new outcome measures should
be developed. Stakeholders should be involved in
this process and qualitative and quantitative
research methods should be used in combination.
c) Multiple primary outcomes addressing distinct
dimensions may be used, if appropriate. The use
of multiple primary outcomes should be
addressed in the sample size calculation and
statistical analysis plan.
d) Secondary outcome measures should capture
relevant patient-centered dimensions of the
respective disease/condition (both self-reported
and biological, as well as outcomes relevant within
the CM model for the treated CM diagnoses).
Additional secondary outcomes might, if appropriate,
include measures of collateral effects (i.e., positive
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experience, often seemingly unrelated to the main
outcomes).
13)Timing
a) Outcomes should be evaluated over a sufficient
long period to capture true impact on chronicity
of disease and to distinguish this from short term
or intermittent relief.
b) The use of multiple intervals to document and
compare the trajectory and persistence of
treatment effects is recommended. Data
collection methods that do not have a direct
influence on the treatment plan (for example, text
messages, phone calls, smart phone applications)
are recommended. However, the frequency of
assessment should be balanced, so that relevant
information is gained without major disruptions
of treatment implementations or practice setting
and with minimal risk of respondent overload.
Study design and statistical analysis
14)Allocation methods
a) Use of appropriate allocation methods is strongly
recommended. Randomization at the level of
individual patients is still the most frequently
used method, but dynamic allocation procedures
(for example, rank minimization) may be used as
an alternative. The final choice depends on the
design of the study and the sites at which the
study will be conducted [37].
b) Stratified randomization or adaptive allocation
techniques may be used to prevent imbalances
for relevant covariates and potential confounders
in study arms [38,39].
c) Partially randomized patient preference designs
have an advantage in that they provide additional
exploratory information as to whether the results
observed for randomized patients are different
from those who were not randomized because of
treatment preferences. However, these designs,
while adding potentially important outcome data
to a clinical trial, are often not feasible because of
the need for much larger sample sizes and higher
costs [40].
d) Cluster randomization is the best approach under
circumstances where the randomization of social
units (for example, clinics) is advisable to avoid
contamination of treatments between groups.
When planning such a trial, it is necessary to
consult the relevant literature and local
institutional roles to determine from whom,
when, and how informed consent must be
obtained [41], and to take into account that a
larger sample might be needed than in patient
level randomized trials [42], because the trials are
powered based on the number of participating
units.
e) Standard procedures ensuring allocation
concealment (for example, central randomization
or secure databases) should be employed.
15)Blinding
a) Blinded outcome measurement (for example, a
blinded rater) is recommended in order to reduce
bias, especially for outcomes that, in usual clinical
practice, are assessed by the practitioner (for
example, physical assessments). Methods to
minimize the risk of unblinding (for example,
allocation concealment, rater training,
standardized assessment protocol) should be
employed.
b) Data analyses should be blinded whenever
possible.
c) Outcomes data reported by patients for the study
purpose (for example, quality of life assessment)
should be kept inaccessible to the practitioner
(for example, by using sealed envelopes or
preferably by sending questionnaires directly to a
study office independent of the study site or using
a blinded interviewer).
d) Recommendations for blinding the treatment (for
example, when using a double dummy placebo
for the comparison of herbal medicine with
conventional drugs) are provided in the
guidelines developed in the European Union
funded GP-TCM project [43].
16)Patient preferences and expectations
a) Patient preferences should, if appropriate, be
acknowledged in the study design, e.g., by using a
partially randomized patient preference design. If
such a design is not feasible, then it is important
to document both the patients’ preferences
regarding the treatment options available in the
trial as well as the degree of their knowledge and
experience with these treatment options.
b) Assessing patient and practitioner preferences
and expectations for the treatments offered in the
study at baseline should be considered. In
randomized trials they should be assessed before
randomization and for all available treatment
options.
17)Sample size
a) Sample size should focus on the main outcome(s)
and the minimum clinically important difference
(MCID) for the respective outcome(s) and take
into account greater heterogeneity in CER study
populations. Because of this, researchers should
specifically avoid conducting small trials (< 50
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specific reason to do such studies (for example,
pilot studies to test feasibility and recruitment).
18)Subgroups
a) Relevant subgroups for the disease/condition
under study should be identified based on
existing data and the literature. Also of current
interest are subgroup analyses for different CM
pattern diagnoses and for CM patients who are
naïve/non-naïve to CM. If sample size permits,
further analyses can be carried out for gender,
age, ethnicity, disease severity/duration, treatment
preference and recruitment site.
b) The main subgroup analyses should be
pre-specified in the analysis plan and included in
sample size planning for confirmatory testing.
Further subgroup analyses can be done on an
exploratory level, but should be stated as an
objective in the study protocol.
19)Statistical analysis
a) Primary analysis for superiority trials of CM
should be pre-specified and intention-to-treat.
In order to assess real-world effectiveness of
treatments, benefits and harms should be compared
in relation to the treatment to which patients were
assigned.
b) Analyses should adjust for relevant potential
confounders (for example, baseline value of the
outcome measure, stratification variables,
expectation, and baseline CM diagnosis).
c) Especially in non-randomized studies, procedures
to compensate for baseline differences must be
used (for example, matching and/or adjusted
analysis).
Economic evaluations
20)Relevance
a) Comparing the effectiveness of treatment options
should be the primary aim of CER, but economic
evaluations should be included whenever possible
as a secondary aim.
b) To allow realistic cost estimates, the setting(s) of
the study should reflect the real-world clinical
practice for each treatment as closely as possible.
If a study includes a standardized and a
non-standardized CM arm, it would be useful to
compare their cost-effectiveness.
21)Methodological approach
a) Standard effectiveness measures for economic
evaluations should be employed that include both
benefits and harms (for example, utility measures
based on SF-36, SF-12 or EQ-5D) [44].
b) Economic evaluations should be designed to
reflect stakeholder perspectives with sensitivity
analysis performed, whenever possible, from
different stakeholder perspectives (for example,
society, payer and patient). Because CM is often
paid out-of-pocket, the patient’s perspective is
highly relevant.
c) Requirements of the local context (for example,
guidelines by regulatory agencies) should be taken
into account.
d) Subgroup analyses should mainly focus on
subgroups defined a priori for the effectiveness
study. Additional analyses should be clearly
described as exploratory. A subgroup analysis for
gender is recommended since there is preliminary
evidence that gender may influence the
cost-effectiveness of CM treatment [45].
e) Exploratory analyses of factors that predict a
better cost-effectiveness are suggested to develop
future hypotheses.
22)Observation time
a) Long-term observations with intermediate
measurement time points are highly
recommended for economic evaluations of
chronic disease in order to evaluate development
of cost-effectiveness over time.
Publication
23)Existing guidelines
To ensure that CER on CM will fulfill reporting
standards, the relevant CONSORT guidelines should
be followed (see Table 1).
24)Content
a) Publication of a detailed study protocol (design
publication) should take place whenever possible
prior to the recruitment of the last patient.
b) The study should be registered in an
internationally accessible trial database with as
many details as possible provided.
c) Publication of the completed study should
describe why and how it qualifies as CER and
make clear the phase of the study.
d) The setting of the study should be described,
including information about the typical care
setting in the country where the study was
performed (and, if relevant, in other countries).
The procedure for selection of practitioners for
each treatment group should be described, with
an account of whether and how those included in
the study differ from the average practitioner (for
example, training, experience).
e) Information on how patients were informed
about the treatment options should be provided.
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group is used, a detailed description with citations
for standard care should be included in the
intervention section.
g) Detailed results of all treatments should be
presented; adherence to interventions and
co-interventions should be reported for each group.
h) Whenever possible, the most relevant subgroup
analyses and analyses of patient characteristics
that predict a better outcome should be published
together with primary results. Detailed subgroup
analysis and/or de-identified patient level data can
be provided as online files.
Discussion
This is the first EGD for clinical research involving a com-
plex and multi-component medical system, providing de-
tailed advice for the design of CER in the field of Chinese
medicine for single as well as multi-component treat-
ments. This EGD has been derived from a systematic de-
velopment process, with active involvement of different
stakeholders from the West and China, and aims to in-
form researchers inside and outside China when designing
their trials. The involvement of China-based stakeholders
reflects both the geographic roots of CM and a growing
interest in CER studies in China. During the development
process, stakeholder groups uncovered a broader under-
standing of the complexity of a multi-component treat-
ment, the cultural differences in CM practice and research
between China and other countries, and the resulting
challenges for the study design. The heterogeneity of CM
as practiced in different countries made it necessary to de-
velop recommendations that account for these variances
of style and context. China has a strong research focus on
herbal medicine, however this is less common in other
countries due to regulatory requirements. Herbal medi-
cine trials have unique challenges and within this consen-
sus process we were only able to discuss the most
prominent ones. For CM herbal medicine trials, it is rec-
ommended that the guidelines for randomized controlled
trials investigating Chinese herbal medicine be utilized
[28]. A limitation of consensus procedures is that not all
aspects of the study design can be addressed. For example,
no recommendations for the study sites were discussed.
There was discussion about the adequacy of compari-
son groups, but because of the broad range of optional
research questions and the multifold combination of in-
terventions, no detailed recommendations were made.
However, there was consensus that the comparison
group(s) should have the option for best practice and
should be based on guidelines or broad expert consen-
sus as recommended under point 7.
Within the process, several methodological aspects
unique to CM were identified that need further research
and clarification. For example, the CM diagnosis classifica-
tion system and the heterogeneity of its application need
research to ensure overall validity and reliability. Another
example is that the CM treatment benefits should also be
measurable in CM terms. This goal may be complicated
by aspects of CM’s explanatory model that aims to restor-
ing balance or increasing resilience, for which suitable out-
come measures are not yet developed.
Conclusion
Although CONSORT statements provide guidelines for
reporting studies, EGDs provide recommendations for the
design of future studies and can contribute to a more stra-
tegic use of limited research resources as well as greater
consistency in trial design. In particular, the present EGD
provides the first set of systematic methodological guid-
ance for future CER on CM.
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